Compare IDEXX Laboratories, Inc. (IDXX) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs McCormick & Company, Incorporated — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while McCormick & Company, Incorporated trades at $44.91 (market cap $12.39B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.3× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and McCormick & Company, Incorporated for 67 Days on average.
| IDXX | MKC | |
|---|---|---|
Market Cap | $40.43B | $12.39B |
Volume | 692,164 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $71.65 |
52-Week Low | $504.70 | $44.14 |
Typical Hold Time | 46 Days | 67 Days |
Enterprise Value | $41.32B | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
MKC trades at $45.25, down 0.33% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 8.31. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Recent dividend declaration of $0.48 per share provides income support. Revenue growth has been steady, reaching $6.84B in 2025 with net income of $789.4M.
The stock presents value opportunity with below-sector P/E ratio and consistent profitability (19.39% net margin), though technical indicators signal near-term weakness. Analyst consensus is mixed with 33% buy ratings but $53.50 price target suggests 18% upside. Key risks include integration challenges from acquisitions and consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
